Cargando…

Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients

Despite the rising public awareness of the risk factors and the possible prevention of melanoma development, it remains challenging in terms of diagnosis and treatment. To improve the clinical situation of patients, it would be especially beneficial to develop prognostic methods for the effective an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamińska, Paula, Buszka, Karolina, Galus, Łukasz, Jankowski, Maurycy, Nowicki, Michał, Mackiewicz, Jacek, Kaczmarek, Mariusz, Budna-Tukan, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047426/ https://www.ncbi.nlm.nih.gov/pubmed/36980196 http://dx.doi.org/10.3390/cells12060856

Ejemplares similares

Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring
por: Kamińska, Paula, et al.
Publicado: (2021)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
por: Tomela, Katarzyna, et al.
Publicado: (2023)

Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer
por: Buszka, Karolina, et al.
Publicado: (2022)

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
por: Pietrzak, Bernadeta, et al.
Publicado: (2022)

Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization
por: Przybyla, Anna, et al.
Publicado: (2021)

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients
por: Kwiatkowska-Borowczyk, Eliza, et al.
Publicado: (2018)

Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6
por: Czerwinska, Patrycja, et al.
Publicado: (2020)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
por: Cieślikowski, Wojciech A., et al.
Publicado: (2021)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
por: Mackiewicz, Jacek, et al.
Publicado: (2017)

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
por: Rogala, Paweł, et al.
Publicado: (2022)

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
por: Rogala, Paweł, et al.
Publicado: (2022)

“Biological Adhesion” is a Significantly Regulated Molecular Process during Long-Term Primary In Vitro Culture of Oviductal Epithelial Cells (Oecs): A Transcriptomic and Proteomic Study
por: Budna-Tukan, Joanna, et al.
Publicado: (2019)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor
por: Kolenda, Tomasz, et al.
Publicado: (2019)

Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient
por: Mackiewicz-Wysocka, Małgorzata, et al.
Publicado: (2014)

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

What is new in the treatment of advanced melanoma? State of the art
por: Mackiewicz, Jacek
Publicado: (2012)

Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or BRAF/MEK Targeted Therapy: Multicenter Real-World Report
por: Placzke, Joanna, et al.
Publicado: (2023)

MicroRNA in lung cancer—a novel potential way for early diagnosis and therapy
por: Frydrychowicz, Magdalena, et al.
Publicado: (2023)

Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model
por: Gąbka-Buszek, Agnieszka, et al.
Publicado: (2020)

Enhanced Suppressive Activity of Regulatory T Cells in the Microenvironment of Malignant Pleural Effusions
por: Budna, Joanna, et al.
Publicado: (2018)

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer
por: Cieślikowski, Wojciech A., et al.
Publicado: (2023)

Recent advances in melanoma treatment – American Society of Clinical Oncology (ASCO) 2012 perspective
por: Mackiewicz, Jacek, et al.
Publicado: (2012)

Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients.
por: Hershey, P., et al.
Publicado: (1978)

Expression Profile of Genes Regulating Steroid Biosynthesis and Metabolism in Human Ovarian Granulosa Cells—A Primary Culture Approach
por: Kranc, Wiesława, et al.
Publicado: (2017)

TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment
por: Kawashima, Shusuke, et al.
Publicado: (2021)

TIGIT(+) NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
por: Tsakmaklis, Anastasia, et al.
Publicado: (2023)

Transcriptomic Pattern of Genes Regulating Protein Response and Status of Mitochondrial Activity Are Related to Oocyte Maturational Competence—A Transcriptomic Study
por: Chermuła, Błażej, et al.
Publicado: (2019)

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma
por: Jacek, Mackiewicz, et al.
Publicado: (2015)

Novel markers of human ovarian granulosa cell differentiation toward osteoblast lineage: A microarray approach
por: Brązert, Maciej, et al.
Publicado: (2019)

Novel markers of human ovarian granulosa cell differentiation toward osteoblast lineage: A microarray approach
por: Brązert, Maciej, et al.
Publicado: (2021)

DNAM1 and TIGIT balance the T cell response, with low T cell TIGIT expression corresponding to inflammation in psoriatic disease
por: Jacobs, Marleen E, et al.
Publicado: (2020)

A Novel and Effective Method for Human Primary Skin Melanocytes and Metastatic Melanoma Cell Isolation
por: Ścieżyńska, Aneta, et al.
Publicado: (2021)

Expression Profile of New Marker Genes Involved in Differentiation of Canine Adipose-Derived Stem Cells into Osteoblasts
por: Jankowski, Maurycy, et al.
Publicado: (2021)

Expression Profile of New Gene Markers Involved in Differentiation of Canine Adipose-Derived Stem Cells into Chondrocytes
por: Jankowski, Maurycy, et al.
Publicado: (2022)

Dynamic Expressions of TIGIT on Splenic T Cells and TIGIT-Mediated Splenic T Cell Dysfunction of Mice With Chronic Toxoplasma gondii Infection
por: Li, Haoran, et al.
Publicado: (2021)

Autotaxin: Its Role in Biology of Melanoma Cells and as a Pharmacological Target
por: Jankowski, Maciej
Publicado: (2011)

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
por: Punt, Simone, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qf451qmgdiuf3688bd5mu9hg5e